BioSpace News Archive

Baylis Medical, a Canadian-based medical device company specializing in cardiology and spine, announced that it is partnering with Ventilators for Canadians, a consortium of Canadian manufacturers, to manufacture ventilators for hospitals across Canada.

The National Kidney Registry and Viracor Eurofins announced a partnership to deliver the newly released COVID-19 antibody testing for NKR’s vast network of Member Centers.

Agenus Inc., an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, announced that the U.S. Food and Drug Administration has granted Agenus Fast Track designation for investigation of balstilimab for the treatment of cervical cancer.

GenMark Diagnostics, Inc. provided preliminary financial and operational results for the quarter ended March 31, 2020 and increased its full year 2020 revenue guidance.

Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced the grant of options to purchase 127,500 shares of its common stock to nine new employees.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the company will participate in the 19th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference.

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced a restructuring intended to enable the Company to advance its corporate strategy and pipeline.

Acceleron Pharma Inc. announced that Jean George is retiring from her position on its Board of Directors.

Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance (LRA), announced today that it is embarking on a clinical study to assess the potential benefit of hydroxychloroquine and/or other lupus therapies in preventing or reducing the symptoms of COVID-19 in people with lupus.

The generous donation will help support COVID-19 relief efforts, hospital programming and technology